Latest News and Press Releases

MAPS brings MDMA-assisted therapy training to Poland for the first time, awarding scholarships to 20 practitioners from war-affected Ukraine and Palestine.

SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve...

Austin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Psychedelic Drugs Market Size & Growth Outlook According to SNS Insider, the global Psychedelic Drugs Market was valued at USD 3.63 billion in 2024 and...

Nearly 60 Ukrainian therapists will attend the event at no cost, learning fundamentals and best practices for psychedelic-assisted therapiesMore than 300 practitioners from more than 30 countries have...

MAPS, which has incubated and funded cutting-edge psychedelic research for decades, is continuing to advance our understanding of psychedelic-assisted therapiesThis study is one of the first trials...

MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...

The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.

MAPS shares ownership of Lykos with mission-aligned investors, will continue to advance psychedelic research, change drug policy, and shape culture

The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS

SAN JOSE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) today announced that the Steven & Alexandra Cohen Foundation has awarded MAPS...